These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 16856917

  • 1. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
    Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA.
    Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
    [Abstract] [Full Text] [Related]

  • 2. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K, Prins C, Saurat JH, French LE.
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L.
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B, Schulz M, Franke I, Gollnick H.
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [Abstract] [Full Text] [Related]

  • 10. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
    Viguier M, Bachelez H, Brice P, Rivet J, Dubertret L.
    Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.
    Peñate Y, Hernández-Machín B, Pérez-Méndez LI, Santiago F, Rosales B, Servitje O, Estrach T, Fernández-Guarino M, Calzado L, Acebo E, Gallardo F, Salar A, Izu R, Ortiz-Romero PL, Pujol RM, Fernández-de-Misa R.
    Br J Dermatol; 2012 Jul; 167(1):174-9. PubMed ID: 22356294
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
    Abasq C, Duval-Modeste AB, Courville P, Joly P.
    Ann Dermatol Venereol; 2008 Jul; 135(6-7):509-11. PubMed ID: 18598807
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Symmetrical primary cutaneous marginal zone lymphoma associated with rheumatoid arthritis.
    Yildirim FE, Karaduman A, Hürmüz P, Ozyar E, Barişta I, Sağlam A.
    J Cutan Pathol; 2010 May; 37(5):600-4. PubMed ID: 19674036
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases.
    Hoefnagel JJ, Vermeer MH, Jansen PM, Heule F, van Voorst Vader PC, Sanders CJ, Gerritsen MJ, Geerts ML, Meijer CJ, Noordijk EM, Willemze R.
    Arch Dermatol; 2005 Sep; 141(9):1139-45. PubMed ID: 16172311
    [Abstract] [Full Text] [Related]

  • 20. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
    Eberle FC, Holstein J, Scheu A, Fend F, Yazdi AS.
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.